Reported 1 day ago
In its Q2 2025 investor letter, Renaissance Investment Management highlighted Thermo Fisher Scientific Inc. (TMO) as an underperformer, reporting an 18.5% decline in stock value despite solid operating results. The company's lowered full-year guidance due to tariff-related issues and funding delays from the National Institute of Health added to investor concerns. While TMO showed a revenue growth of 3% to $10.85 billion in the second quarter, its share value has fallen significantly, losing 21.70% over the past year.
Source: YAHOO